Efficacy and safety of once-weekly somatrogon following up to 4 years of treatment in Japanese children with growth hormone deficiency: results from an open-label extension of a phase 3 study
Endocrine Journal · 2026 · 73 (1) · 21-32
DOI: 10.1507/endocrj.ej24-0625 ↗Kurz gefasst
Klinische Studie (Phase III) in der Zeitschrift Endocrine Journal, 2026. Verfasst von Reiko Horikawa und 13 weiteren Autor:innen. Beteiligte Einrichtung: Division of Endocrinology and Metabolism, National Center for Child Health and Development, Tokyo, Japan. Hauptthemen laut MEDLINE: Human Growth Hormone, Growth Disorders, Dwarfism, Pituitary. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 23 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: OPKO Health, Pfizer Japan.
Themen: Kinderkrankenpflege
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Endocrinology and Metabolism, National Center for Child Health and Development, Tokyo, Japan.
- Tanaka Growth Clinic, Tokyo, Japan.
- Department of Endocrinology and Metabolism, Tokyo Metropolitan Children's Medical Center, Tokyo, Japan.
- 2nd Department of Internal Medicine, Date Red Cross Hospital, Hokkaido, Japan.
- WuXi Clinical, Austin, TX, USA.
- Oregon Health & Science University, Portland, OR, USA.
Förderung
- OPKO Health
- Pfizer Japan
Zitieren
APA
Horikawa, R., Tanaka, T., Hasegawa, Y., Yorifuji, T., Ng, D., Rosenfeld, R. G., Hoshino, Y., Okayama, A., Ebata, N., Hosoi, M., Nakamuta, S., Gomez, R., Pastrak, A., & Castellanos, O. (2026). Efficacy and safety of once-weekly somatrogon following up to 4 years of treatment in Japanese children with growth hormone deficiency: results from an open-label extension of a phase 3 study. Endocrine Journal, 73(1), 21-32. https://doi.org/10.1507/endocrj.ej24-0625
Vancouver
Horikawa R, Tanaka T, Hasegawa Y, Yorifuji T, Ng D, Rosenfeld RG, et al. Efficacy and safety of once-weekly somatrogon following up to 4 years of treatment in Japanese children with growth hormone deficiency: results from an open-label extension of a phase 3 study. Endocrine Journal. 2026;73(1):21-32. doi:10.1507/endocrj.ej24-0625
BibTeX
@article{Horikawa2026,
author = {Horikawa, Reiko and Tanaka, Toshiaki and Hasegawa, Yukihiro and Yorifuji, Tohru and Ng, David and Rosenfeld, Ron G and Hoshino, Yuko and Okayama, Akifumi and Ebata, Nozomi and Hosoi, Masayoshi and Nakamuta, Shinichi and Gomez, Roy and Pastrak, Aleksandra and Castellanos, Orlando},
title = {Efficacy and safety of once-weekly somatrogon following up to 4 years of treatment in Japanese children with growth hormone deficiency: results from an open-label extension of a phase 3 study},
journal = {Endocrine Journal},
year = {2026},
volume = {73},
number = {1},
pages = {21--32},
doi = {10.1507/endocrj.ej24-0625}
}
EUVIMED